Advertisement

Secondary Hypertension: Adrenal and Nervous Systems

  • Emmanuel L. Bravo
Part of the Atlas of Heart Diseases book series (AD)

Abstract

In a preponderance of cases of hypertension, the cause is not clear. Such cases are usually termed essential hypertension. In the remainder, a specific cause can be identified. The percentage of individuals with so-called secondary hypertension ranges from above 5% of all hypertensive patients presenting in a community clinical practice to more than 30% in referral centers. It is especially important to identify patients with secondary hypertension because correction of the cause will often cure—not merely palliate—the disorder. Of equal importance is the fact that detailed study of patients with secondary hypertension may offer important clues regarding the cause and management of essential hypertension.

Keywords

Plasma Renin Activity Primary Aldosteronism Secondary Hypertension Zona Glomerulosa Inferior Petrosal Sinus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rodriguez-Portales JA, Arteaga E, Lopez-Morena JR, et al.: Zona glomerulosa function after lifelong suppression in two siblings with the hypertensive virilizing form of congential adrenal hyperplasia. J Clin Endocrinol Metab 1988, 66: 349–354PubMedCrossRefGoogle Scholar
  2. 2.
    Biglieri EG, Herron MA, Brust N: 17-Hydroxylation deficiency in man. J Clin Invest 1966, 45: 1946–1954.PubMedCrossRefGoogle Scholar
  3. 3.
    Saadi HF, Bravo EL, Aron DC: Feminizing adrenocortical tumor: steroid hormone response to ketoconazole. J Clin Endocrinol Metab 1990, 70: 540–543PubMedCrossRefGoogle Scholar
  4. 4.
    Azziz R, Boots LR, Parker CR, et al.: 11 ß-Hydroxylase deficiency in hyperandrogenism. Fertil Steril 1991, 55: 733–741.PubMedGoogle Scholar
  5. 5.
    Forsham PH: The adrenal cortex. In Textbook of Endocrinology, edn 4. Edited by Williams RH. Philadelphia: WB Saunders; 1968: 287–379.Google Scholar
  6. 6.
    Bravo EL: What to do when potassium is low or high. Diagnosis 1988, 10: 1–6.Google Scholar
  7. 7.
    Liddle GW, Bledsoe T, Coppage WS: A familial renal disorder stimulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963, 76: 19.Google Scholar
  8. 8.
    Botero-Velez M, Curtis JJ, Warnock DG: Liddle’s syndrome revisited: a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 300: 178–181.CrossRefGoogle Scholar
  9. 9.
    Oldfield EH, Chrousos GP, Schulte HM, et al.: Preoperative localization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 1985, 312: 100–103.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamilaris TC, Chrousos GP: Adrenal diseases. In Diagnostic Endocrinology. Edited by Moore WT, Eastman RC. Philadelphia: BC Decker; 1990: 79–199.Google Scholar
  11. 11.
    Arriza JL, Weinberger C, Cerelli G: Cloning of human mineralo-corticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237: 268–275.PubMedCrossRefGoogle Scholar
  12. 12.
    Edwards CRW, Stewart PM, Burt D, et al.: Localization of 11 ß-hydroxysteroid dehydrogenase: tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2: 986–989.PubMedCrossRefGoogle Scholar
  13. 13.
    Funder JW, Pearce PT, Smith R, et al.: Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242: 583–585.PubMedCrossRefGoogle Scholar
  14. 14.
    Brem AS, Matheson KL, Conca T, et al.: Effect of carbenoxolone on glucocorticoid metabolism and Na transport in toad bladder. Am J Physiol 1989, 257: 700–704.Google Scholar
  15. 15.
    Farese RV, Biglieri EG, Shackleton CHL, et al.: Licorice-induced hypermineralocorticoidism. N Engl J Med 1991, 325: 1223–1227.PubMedCrossRefGoogle Scholar
  16. 16.
    Walker BR, Edwards ERW: Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 1994, 23: 359–377.PubMedGoogle Scholar
  17. 17.
    Bravo EL, Tarazi RC, Dustan HP, et al.: The changing clinical spectrum of primary aldosteronism. Am J Med 1983, 74: 641–651.PubMedCrossRefGoogle Scholar
  18. 18.
    Bravo EL: Primary aldosteronism. Urol Clin North Am 1989, 16: 481–486.PubMedGoogle Scholar
  19. 19.
    Bravo EL: Primary aldosteronism. Cardiol Clin 1988, 6: 509–515.PubMedGoogle Scholar
  20. 20.
    Guerin CK, Wahner HW, Gorman CA, et al.: Computed tomographic scanning versus radioisotope imaging in adrenocortical diagnosis. Am J Med 1983, 75: 653–657.PubMedCrossRefGoogle Scholar
  21. 21.
    Bravo EL, Dustan HP, Tarazi RC: Spironolactone as a non-specific treatment for primary aldosteronism. Circulation 1973, 48: 491–498.PubMedCrossRefGoogle Scholar
  22. 22.
    Bravo EL: Calcium channel blockage with nifedipine in primary aldosteronism. Hypertension 1986, 8(suppl I): I-191–I-194.Google Scholar
  23. 23.
    Bravo EL: Pheochromocytoma and mineralocorticoid hypertension. In Current Therapy in Nephrology and Hypertension, 3rd ed. Edited by Glassock RJ. Philadelphia: BC Decker; 1992: 386–391.Google Scholar
  24. 24.
    Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 1999, 131: 105–108.PubMedGoogle Scholar
  25. 25.
    Sutherland DJ, Ruse JL, Laidlaw JC: Hypertension, increased aldosterone secretion, and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966, 95: 1109–1119.PubMedGoogle Scholar
  26. 26.
    Lifton RP, Dluhy RG, Powers M, et al.: A chimeric 11-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355: 262–265.PubMedCrossRefGoogle Scholar
  27. 27.
    Lifton RP, Dluhy RG, Powers M, et al.: Hereditary hypertension caused by chimeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992, 2: 66–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Pascoe L, Curnow KM, Slutsker L, et al.: Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992, 89: 8327–8331.PubMedCrossRefGoogle Scholar
  29. 29.
    Woodland E, Tunny TJ, Hamlet SM, et al.: Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism. Clin Exp Pharmacol Physiol 1985, 12: 245–248.PubMedCrossRefGoogle Scholar
  30. 30.
    Bravo EL: The syndrome of primary aldosteronism and pheochromocytoma. In Diseases of the Kidney. Edited by Shrier RW, Gosschalk CV. Boston: Little, Brown & Co; 1993: 1475–1503.Google Scholar
  31. 31.
    Bravo EL, Gifford RW: Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984, 311: 1298–1303.PubMedCrossRefGoogle Scholar
  32. 32.
    Bravo EL, Tarazi RC, Gifford Jr RW, Stewart BH: Circulating plasma and urinary catecholamines in pheochromocytoma: diagnostic and pathophysiologic implications. N Engl J Med 1979, 301: 682–686.PubMedCrossRefGoogle Scholar
  33. 33.
    Bravo EL, Gifford RW: Pheochromocytoma. In Endocrinology and Metabolism Clinics of North America. Edited by Ober KP. Philadelphia: WB Saunders; 1993: 329–341.Google Scholar
  34. 34.
    Bravo EL: Adrenal medullary function. In Diagnostic Endocrinology. Edited by Moore WT, Eastman RC. Philadelphia: BC Decker; 1990: 217–226.Google Scholar
  35. 35.
    Bravo EL, Gifford RW, Manger WM: Adrenal medullary tumors: pheochromocytoma. In Endocrine Tumors. Edited by Mazzaferri EL, Samaan NA. Boston: Blackwell Scientific Publications; 1993: 426–447.Google Scholar
  36. 36.
    Bravo EL: Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994, 15: 356–368.PubMedGoogle Scholar
  37. 37.
    Taylor SH: Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction. Am Heart J 1988, 16: 1735–1747.CrossRefGoogle Scholar
  38. 38.
    Canale MP, Bravo EL: Calcium channel entry blockers are effective and safe in the preoperative management of pheochromocytoma [abstract]. Hypertension 1993, 21: 560.Google Scholar
  39. 39.
    Sprung J, et al.: Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 2000, in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Emmanuel L. Bravo

There are no affiliations available

Personalised recommendations